SCIB1: Phase I/II halted

Scancell suspended dosing in the open-label, dose-escalation, U.K. Phase I/II SCIB1-001 trial evaluating up to 8 mg intramuscular

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE